Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

Table 2 Treatment Effects by Group

Variable	Δ Metformin(N = 25)	Δ Exenatide(N = 25)	Difference(M – E)	P-Value
BMI (kg/m²)	−0.4 ± 0.7*	−0.8 ± 1.4*	−0.4	0.229
Waist Circumference (cm)	−1.7 ± 3.5*	−3.2 ± 6.2*	−1.5	0.285
Body Fat (%)	0.8 ± 1.7	0.8 ± 2.6	0.0	0.939
SBP (mmHg)	0.5 ± 10.2	−5.4 ± 15.3	−5.9	0.114
DBP (mmHg)	−0.8 ± 6.9	−2.8 ± 7.3	−2.0	0.322
Cholesterol (mg/dL)	−9.2 ± 16.1**	−14.6 ± 17.4***	−5.4	0.264
LDL-Cholesterol (mg/dL)	−1.1 ± 21.4	−9.9 ± 22.5*	−8.8	0.169
HDL-Cholesterol (mg/dL)	−1.5 ± 9.7	−1.1 ± 12.8	0.4	0.901
Triglycerides (mg/dL)	−2.9 ± 22.8	−25.5 ± 45.7*	−22.6	0.032
Glucose (mg/dL)	−3.7 ± 9.3	−2.7 ± 9.9	1.0	0.725
Insulin (mU/L)	−2.4 ± 4.3**	−0.6 ± 2.8	1.8	0.079
HOMA-IR	−0.8 ± 1.4*	−0.2 ± 0.8	0.6	0.094
CRP (mg/L)	−0.4 ± 2.2	−0.4 ± 2.2	0.0	0.987
OxLDL (U/L)	−16.5 ± 30.4*	−0.1 ± 41.5	16.4	0.123
VCAM-1 (ng/mL)	−15.3 ± 101.3	10.4 ± 83.2	25.7	0.336
RHI	−0.17 ± 0.72	0.01 ± 0.68	0.18	0.348

BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic blood pressure; LDL = low density lipoprotein; HDL = high density lipoprotein; HOMA-IR = homeostasis model assessment for insulin resistance; CRP = C-reactive protein; OxLDL = oxidized low density lipoprotein; VCAM-1 = vascular cell adhesion molecule-1; RHI = reactive hyperemic index.
Data are shown as mean ± standard deviation; P-Values represent ANOVA interaction term.
Body fat data were obtained in 35 patients (exenatide N = 17; metformin N = 18).
* denotes P<0.05 for within group treatment effect; ** denotes P<0.01 for within group treatment effect; *** denotes P<0.001 for within group treatment effect.

ISSN: 1475-2840